These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 29901119)

  • 21. Therapeutic editing of hepatocyte genome in vivo.
    Ruiz de Galarreta M; Lujambio A
    J Hepatol; 2017 Oct; 67(4):818-828. PubMed ID: 28527665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome editing comes of age.
    Kim JS
    Nat Protoc; 2016 Sep; 11(9):1573-8. PubMed ID: 27490630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN.
    Ul Ain Q; Chung JY; Kim YH
    J Control Release; 2015 May; 205():120-7. PubMed ID: 25553825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene targeting technologies in rats: zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats.
    Mashimo T
    Dev Growth Differ; 2014 Jan; 56(1):46-52. PubMed ID: 24372523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Editing With TALEN and CRISPR/Cas in Rice.
    Bi H; Yang B
    Prog Mol Biol Transl Sci; 2017; 149():81-98. PubMed ID: 28712502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TALEN- and CRISPR/Cas9-Mediated Gene Editing in Human Pluripotent Stem Cells Using Lipid-Based Transfection.
    Hendriks WT; Jiang X; Daheron L; Cowan CA
    Curr Protoc Stem Cell Biol; 2015 Aug; 34():5B.3.1-5B.3.25. PubMed ID: 26237572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective.
    Ilahibaks NF; Hulsbos MJ; Lei Z; Vader P; Sluijter JPG
    Adv Exp Med Biol; 2023; 1396():315-339. PubMed ID: 36454475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications.
    Ma X; Zhu Q; Chen Y; Liu YG
    Mol Plant; 2016 Jul; 9(7):961-74. PubMed ID: 27108381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific Targeting of Oncogenes Using CRISPR Technology.
    Oppel F; Schürmann M; Goon P; Albers AE; Sudhoff H
    Cancer Res; 2018 Oct; 78(19):5506-5512. PubMed ID: 30194069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic correction using engineered nucleases for gene therapy applications.
    Li HL; Nakano T; Hotta A
    Dev Growth Differ; 2014 Jan; 56(1):63-77. PubMed ID: 24329887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From hacking the human genome to editing organs.
    Tobita T; Guzman-Lepe J; Collin de l'Hortet A
    Organogenesis; 2015; 11(4):173-82. PubMed ID: 26588350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
    Pellagatti A; Dolatshad H; Valletta S; Boultwood J
    Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity.
    Franco-Tormo MJ; Salas-Crisostomo M; Rocha NB; Budde H; Machado S; Murillo-Rodríguez E
    J Mol Neurosci; 2018 May; 65(1):10-16. PubMed ID: 29732484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene editing tools: state-of-the-art and the road ahead for the model and non-model fishes.
    Barman HK; Rasal KD; Chakrapani V; Ninawe AS; Vengayil DT; Asrafuzzaman S; Sundaray JK; Jayasankar P
    Transgenic Res; 2017 Oct; 26(5):577-589. PubMed ID: 28681201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPR/Cas9: a historical and chemical biology perspective of targeted genome engineering.
    Singh A; Chakraborty D; Maiti S
    Chem Soc Rev; 2016 Dec; 45(24):6666-6684. PubMed ID: 27711765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivery methods for site-specific nucleases: Achieving the full potential of therapeutic gene editing.
    Liu J; Shui SL
    J Control Release; 2016 Dec; 244(Pt A):83-97. PubMed ID: 27865852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.